Certara, Inc. (NASDAQ:CERT) Shares Bought by Geneva Capital Management LLC

Geneva Capital Management LLC boosted its stake in Certara, Inc. (NASDAQ:CERT) by 29.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 3,824,850 shares of the company’s stock after acquiring an additional 860,763 shares during the quarter. Certara comprises 1.3% of Geneva Capital Management LLC’s holdings, making the stock its 29th biggest position. Geneva Capital Management LLC’s holdings in Certara were worth $67,279,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. SG Americas Securities LLC increased its stake in shares of Certara by 193.3% during the third quarter. SG Americas Securities LLC now owns 20,047 shares of the company’s stock valued at $291,000 after acquiring an additional 13,213 shares during the period. Commonwealth Equity Services LLC boosted its stake in Certara by 31.2% during the third quarter. Commonwealth Equity Services LLC now owns 19,055 shares of the company’s stock valued at $277,000 after buying an additional 4,528 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Certara by 16.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,117 shares of the company’s stock valued at $351,000 after acquiring an additional 3,482 shares during the last quarter. Strs Ohio boosted its position in shares of Certara by 105.0% during the 3rd quarter. Strs Ohio now owns 72,552 shares of the company’s stock valued at $1,054,000 after purchasing an additional 37,159 shares in the last quarter. Finally, Roubaix Capital LLC acquired a new position in shares of Certara in the 3rd quarter worth approximately $1,999,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Leerink Partnrs restated a “market perform” rating on shares of Certara in a report on Monday, February 26th. SVB Leerink initiated coverage on Certara in a report on Monday, February 26th. They issued a “market perform” rating and a $19.00 target price on the stock. UBS Group increased their price target on Certara from $17.00 to $20.00 and gave the company a “neutral” rating in a research report on Friday, March 1st. Barclays boosted their price objective on Certara from $16.00 to $18.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Finally, JMP Securities initiated coverage on shares of Certara in a research report on Thursday, April 4th. They issued a “market perform” rating on the stock. Seven equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $20.06.

Insider Buying and Selling at Certara

In other news, SVP Richard M. Traynor sold 3,000 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $18.00, for a total transaction of $54,000.00. Following the transaction, the senior vice president now owns 173,524 shares of the company’s stock, valued at approximately $3,123,432. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Certara news, SVP Richard M. Traynor sold 3,000 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $18.00, for a total transaction of $54,000.00. Following the completion of the sale, the senior vice president now directly owns 173,524 shares in the company, valued at $3,123,432. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Patrick F. Smith sold 14,427 shares of the business’s stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total value of $243,094.95. Following the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $844,033.35. The disclosure for this sale can be found here. Insiders have sold a total of 23,427 shares of company stock worth $405,095 over the last three months. Corporate insiders own 2.39% of the company’s stock.

Certara Stock Up 4.3 %

CERT traded up $0.71 during trading on Thursday, reaching $17.06. 555,141 shares of the stock traded hands, compared to its average volume of 537,756. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.62 and a quick ratio of 2.62. Certara, Inc. has a fifty-two week low of $11.81 and a fifty-two week high of $22.65. The stock’s 50-day simple moving average is $17.71 and its two-hundred day simple moving average is $16.44. The stock has a market cap of $2.73 billion, a price-to-earnings ratio of -46.71, a price-to-earnings-growth ratio of 1.81 and a beta of 1.61.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Thursday, February 29th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.04). The firm had revenue of $88.01 million during the quarter, compared to analyst estimates of $86.80 million. Certara had a positive return on equity of 4.33% and a negative net margin of 15.62%. As a group, equities research analysts expect that Certara, Inc. will post 0.29 EPS for the current year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.